Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time…
News
Pfizer shelves haemophilia gene therapy Beqvez amid low demand
UroGen acquires IconOVir’s oncolytic virus assets
NICE green lights two blood cancer therapies for NHS use
Incyte and Genesis collaborate on small-molecule medicines
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
FibroGen sells China unit to AstraZeneca for $160m
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
